Although allopurinol is conventionally used to treat hyperuricemia, available evidence supports its potential benefit as an adjunctive medication not only for schizophrenia [3] but also for epilepsy [9]. Schizophrenic patients are prone to seizures because of comorbid substance abuse, long-term exposure to psychotropic agents that may lower their seizure threshold, or frequent episodes of head injury [5]. Similarly, individuals with epilepsy have a ∼2.5 times higher risk of being diagnosed with schizophrenia [8]. Although the relationship between schizophrenia and epilepsy remains controversial, both conditions share several common features, such as ventricular enlargement, temporal lobe pathology, neuropsychology, and genetic factors [2]. However, few reports focus on therapeutic strategies for schizophrenic patients with epilepsy. Here, we present a case of treatment-resistant schizophrenia presenting with post-traumatic epilepsy as a sequel of subdural hemorrhage (SDH). The patient's positive symptoms and seizure attacks were significantly improved after allopurinol augmentation.
References
1
Brundege JM, Dunwiddie TV.
Role of adenosine as a modulator of synaptic activity in the central nervous system.
Adv Pharmacol.
1997;
39
353-391
7
Lara DR, Dall’Igna OP, Ghisolfi ES. et al .
Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications.
Prog Neuropsychopharmacol Biol Psychiatry.
2006;
30
617-629
8
Qin P, Xu H, Laursen TM. et al .
Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study.
Br Med J.
2005;
331
23
9
Togha M, Akhondzadeh S, Motamedi M. et al .
Allopurinol as adjunctive therapy in intractable epilepsy: a double-blind and placebo-controlled trial.
Arch Med Res.
2007;
38
313-316
